Your browser doesn't support javascript.
loading
Pharmacokinetics of lincomycin following single intravenous administration in buffalo calves.
Sreeshitha Gouri, Sreedharan; Venkatachalam, Dinakaran; Dumka, Vinod Kumar.
  • Sreeshitha Gouri S; Department of Veterinary Pharmacology and Toxicology, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, 141004, India.
Trop Anim Health Prod ; 46(6): 1099-102, 2014 Aug.
Article en En | MEDLINE | ID: mdl-24792222
ABSTRACT
Lincomycin 10 mg kg(-1), IV in buffalo calves followed two-compartment open model with high distribution rate constant α (11.2 ± 0.42 h(-1)) and K 12/K 21 ratio (4.40 ± 0.10). Distribution half-life was 0.06 ± 0.01 h and AUC was 41.6 ± 1.73 µg mL(-1) h. Large Vdarea (1.15 ± 0.03 L kg(-1)) indicated good distribution of lincomycin in various body fluids and tissues. Peak plasma level of lincomycin (71.8 ± 1.83 µg mL(-1)) was observed at 1 min as expected by IV route. The elimination half-life and MRT of lincomycin were short (3.30 ± 0.08 and 4.32 ± 0.11 h, respectively). Lincomycin 10 mg kg(-1) IV at 12-h interval would be sufficient to maintain T > MIC above 60 % for bacteria with minimum inhibitory concentrations (MIC) values ≤1.6 µg mL(-1). Favourable pharmacokinetic profile in buffalo calves and a convenient dosing interval suggest that lincomycin may be an appropriate antibacterial in buffalo species for gram-positive and anaerobic bacterial pathogens susceptible to lincomycin.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Búfalos / Lincomicina / Antibacterianos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Búfalos / Lincomicina / Antibacterianos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2014 Tipo del documento: Article